GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Asset Turnover

THAR (Tharimmune) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Tharimmune's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Tharimmune's Total Assets for the quarter that ended in Sep. 2024 was $6.75 Mil. Therefore, Tharimmune's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Tharimmune's annualized ROE % for the quarter that ended in Sep. 2024 was -312.69%. It is also linked to ROA % through Du Pont Formula. Tharimmune's annualized ROA % for the quarter that ended in Sep. 2024 was -224.81%.


Tharimmune Asset Turnover Historical Data

The historical data trend for Tharimmune's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Asset Turnover Chart

Tharimmune Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Tharimmune Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tharimmune's Asset Turnover

For the Biotechnology subindustry, Tharimmune's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tharimmune's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tharimmune's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Tharimmune's Asset Turnover falls into.



Tharimmune Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Tharimmune's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (6.689+10.946)/ 2 )
=0/8.8175
=0.00

Tharimmune's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (8.257+5.251)/ 2 )
=0/6.754
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Tharimmune  (NAS:THAR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Tharimmune's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-15.184/4.856
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-15.184 / 0)*(0 / 6.754)*(6.754/ 4.856)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.3909
=ROA %*Equity Multiplier
=-224.81 %*1.3909
=-312.69 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Tharimmune's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-15.184/6.754
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-15.184 / 0)*(0 / 6.754)
=Net Margin %*Asset Turnover
= %*0
=-224.81 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Tharimmune Asset Turnover Related Terms

Thank you for viewing the detailed overview of Tharimmune's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Tharimmune Business Description

Traded in Other Exchanges
N/A
Address
1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Executives
Randy Milby director, officer: Chief Executive Officer 5 JACK LANE, NEWARK DE 19711
Sireesh Appajosyula director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas 10 percent owner 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess officer: Chief Financial Officer 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Lynne A. Bui director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc 10 percent owner 16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc 10 percent owner 179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807